Home Cart 0 Sign in  
X

[ CAS No. 474706-74-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 474706-74-6
Chemical Structure| 474706-74-6
Chemical Structure| 474706-74-6
Structure of 474706-74-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 474706-74-6 ]

Related Doc. of [ 474706-74-6 ]

Alternatived Products of [ 474706-74-6 ]

Product Details of [ 474706-74-6 ]

CAS No. :474706-74-6 MDL No. :MFCD18800553
Formula : C7H4BrIN2 Boiling Point : -
Linear Structure Formula :- InChI Key :VADGFPDSVWQCHR-UHFFFAOYSA-N
M.W : 322.93 Pubchem ID :22031632
Synonyms :

Calculated chemistry of [ 474706-74-6 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 9
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 0.0
Molar Refractivity : 55.61
TPSA : 17.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.04 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.37
Log Po/w (XLOGP3) : 3.14
Log Po/w (WLOGP) : 2.7
Log Po/w (MLOGP) : 2.35
Log Po/w (SILICOS-IT) : 2.59
Consensus Log Po/w : 2.63

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.43
Solubility : 0.0121 mg/ml ; 0.0000375 mol/l
Class : Moderately soluble
Log S (Ali) : -3.17
Solubility : 0.217 mg/ml ; 0.000672 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.87
Solubility : 0.0441 mg/ml ; 0.000136 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.28

Safety of [ 474706-74-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 474706-74-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 474706-74-6 ]
  • Downstream synthetic route of [ 474706-74-6 ]

[ 474706-74-6 ] Synthesis Path-Upstream   1~3

  • 1
  • [ 474706-74-6 ]
  • [ 541-41-3 ]
  • [ 372198-69-1 ]
Reference: [1] Patent: EP1382603, 2004, A1, . Location in patent: Page 144
  • 2
  • [ 6188-23-4 ]
  • [ 474706-74-6 ]
YieldReaction ConditionsOperation in experiment
96% With N-iodo-succinimide In acetonitrile at 20℃; for 1 h; To a solution of 6-bromoimidazo[1,2-a]pyridine (721 mg 3.66 mmol) in 20 mL ACN were added 988 mg (4.39 mmol) of N-iodosuccinimide. The reaction was stirred at room temperature for 1 h. Solvent was removed in vacuo then residue was diluted with CH2Cl2 and washed successively with 10percent NaOH aqueous solution, saturated thiosulfate solution and then with water. The organic layer was dried over magnesium sulfate and concentrated in vacuo to afford the desired product as a white solid (1.18 g), 96percent yield, mp 209 °C; IR (ATR) ν (cm-1) 3024. 1516. 711. 698. 1H NMR (400 MHz, CDCl3) δ 7.29 (dd, J=9.6, 1.8 Hz, 1H), 7.51 (d, J=9.6 Hz, 1H), 7.70 (s, 1H), 8.26-8.28 (m, 1H). 13C NMR (100.6 MHz, CDCl3) δ 61.4, 108.4, 118.6, 126.4, 128.6, 128.6, 141.1, 146.5. HRMS (EI) m/z calcd for C7H4BrIN2 [M+H]+: 322.8675, found: 322.8678.
77% With N-iodo-succinimide In acetonitrile for 16.0833 h; To a slightly cloudy mixture of 6-bromoimidazo[l,2-α]pyridine (15.4 g, 78.0 mmol) in dry MeCN (500 mL) was added jV-iodosuccinimide (17.6 g, 78.0 mmol) portionwise over ~5 min (a precipitate immediately formed). After 16 h, the crude product was collected by filtration and triturated with boiling MeCN to provide 19.56 g (77percent) of the title compound as an off-white solid. MS(ES)+ m/e 198.7 [M+H]+.
67% With N-iodo-succinimide In acetonitrile at 20℃; for 5 h; Step: 1 To a solution of 6-bromoimidazo [l ,2-a]pyridine (20 g, 101.5 mmol) in ACN (300 mL) was added N-iodosuccinimide (22.8 g, 101.5 mmol) at rt and stirred for 5 h. The reaction mixture was filtered and washed with hot acetonitrile to afford 6-bromo-3-iodoimidazo[l,2- ajpyridine (22 g, 67percent) as a pale yellow solid. 1H NMR (400 MHz, CDC13) δ 8.29 (s, 1H), 7.58 (d, J= 9.2 Hz, 1H), 7.35 (d, J= 7.6 Hz, 1H), 7.27 (s, 1H).
67% With N-iodo-succinimide In acetonitrile at 20℃; for 5 h; To a solution of 6-bromoimidazo[1,2-a]pyridine (20 g, 101.5 mmol) in ACN (300 mL) was added N-iodosuccinimide (22.8 g, 101.5 mmol) at rt and stirred for 5 h.
The reaction mixture was filtered and washed with hot acetonitrile to afford 6-bromo-3-iodoimidazo[1,2-a]pyridine (22 g, 67percent) as a pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.29 (s, 1H), 7.58 (d, J=9.2 Hz, 1H), 7.35 (d, J=7.6 Hz, 1H), 7.27 (s, 1H).
51% With N-iodo-succinimide In acetonitrile at 20℃; for 1 h; To a solution of 6-bromoimidazo[1,2-a]pyridine (5 g, 25.4 mmol) in CH3CN (139 mL) was added NIS (6.85 g, 30.5 mmol). The reaction was stirred at r.t. for 1 hour and the reaction was concentrated. The residue was diluted with DCM (140 mL) and washed with 100 mL of 10 percent NaOH, 100 mL of saturated thiosulfate solution, and then 100 mL of water. The organic layer was dried over MgSO4, filtered and concentrated. The material was isolated as a beige solid (4.163 g, 51 percent yield).1H NMR (400 MHz, CDCl3) δ 8.28– 8.27 (m, 1H), 7.69 (s, 1H), 7.51 (dd, J = 1.2, 12.8 Hz, 1H), 7.29 (dd, J = 2.8, 12.8 Hz, 1H). This material had spectra that were indistinguishable from the literature.

Reference: [1] Tetrahedron, 2011, vol. 67, # 37, p. 7128 - 7138
[2] Journal of Medicinal Chemistry, 2011, vol. 54, # 7, p. 2455 - 2466
[3] Patent: WO2008/14219, 2008, A2, . Location in patent: Page/Page column 45
[4] Patent: WO2013/147711, 2013, A1, . Location in patent: Page/Page column 248
[5] Patent: US2014/371199, 2014, A1, . Location in patent: Paragraph 0852
[6] Patent: WO2017/197151, 2017, A1, . Location in patent: Page/Page column 41
[7] Patent: EP1382603, 2004, A1, . Location in patent: Page 57; 58
[8] Patent: WO2010/108074, 2010, A2, . Location in patent: Page/Page column 53-54
[9] Patent: WO2015/188369, 2015, A1, . Location in patent: Page/Page column 88; 89
  • 3
  • [ 1072-97-5 ]
  • [ 474706-74-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 7, p. 2455 - 2466
[2] Tetrahedron, 2011, vol. 67, # 37, p. 7128 - 7138
[3] Patent: WO2015/188369, 2015, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 474706-74-6 ]

Bromides

Chemical Structure| 6188-23-4

[ 6188-23-4 ]

6-Bromoimidazo[1,2-a]pyridine

Similarity: 0.82

Chemical Structure| 116355-18-1

[ 116355-18-1 ]

6-Bromo-7-methylimidazo[1,2-a]pyridine

Similarity: 0.78

Chemical Structure| 808744-34-5

[ 808744-34-5 ]

7-Bromoimidazo[1,2-a]pyridine

Similarity: 0.75

Chemical Structure| 217435-65-9

[ 217435-65-9 ]

6-Bromo-8-methylimidazo[1,2-a]pyridine

Similarity: 0.74

Chemical Structure| 947248-52-4

[ 947248-52-4 ]

6-Bromoimidazo[1,2-a]pyridin-2-amine

Similarity: 0.74

Related Parent Nucleus of
[ 474706-74-6 ]

Other Aromatic Heterocycles

Chemical Structure| 307503-19-1

[ 307503-19-1 ]

3-Iodoimidazo[1,2-a]pyridine

Similarity: 0.86

Chemical Structure| 6188-23-4

[ 6188-23-4 ]

6-Bromoimidazo[1,2-a]pyridine

Similarity: 0.82

Chemical Structure| 116355-18-1

[ 116355-18-1 ]

6-Bromo-7-methylimidazo[1,2-a]pyridine

Similarity: 0.78

Chemical Structure| 885275-59-2

[ 885275-59-2 ]

6-Chloro-3-iodoimidazo[1,2-a]pyridine

Similarity: 0.76

Chemical Structure| 808744-34-5

[ 808744-34-5 ]

7-Bromoimidazo[1,2-a]pyridine

Similarity: 0.75